Ramsay, Stattman, Vela & Price, Inc. Biogen Inc. Transaction History
Ramsay, Stattman, Vela & Price, Inc.
- $525 Million
- Q3 2024
A detailed history of Ramsay, Stattman, Vela & Price, Inc. transactions in Biogen Inc. stock. As of the latest transaction made, Ramsay, Stattman, Vela & Price, Inc. holds 4,545 shares of BIIB stock, worth $781,876. This represents 0.17% of its overall portfolio holdings.
Number of Shares
4,545
Previous 7,545
39.76%
Holding current value
$781,876
Previous $1.75 Million
49.63%
% of portfolio
0.17%
Previous 0.34%
Shares
5 transactions
Others Institutions Holding BIIB
# of Institutions
1,014Shares Held
128MCall Options Held
1.22MPut Options Held
1.4M-
Vanguard Group Inc Valley Forge, PA16.6MShares$2.86 Billion0.08% of portfolio
-
Primecap Management CO Pasadena, CA16.3MShares$2.81 Billion2.37% of portfolio
-
Black Rock Inc. New York, NY14.5MShares$2.5 Billion0.08% of portfolio
-
State Street Corp Boston, MA7.1MShares$1.22 Billion0.07% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.68MShares$977 Million0.83% of portfolio
About BIOGEN INC.
- Ticker BIIB
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 144,000,992
- Market Cap $24.8B
- Description
- Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...